NR4A1 and breast carcinoma: Hormone receptor positive (HR+) breast cancer is the most common subtype of BC, accounting for 70% of all breast cancer population (7), in which endocrine therapy (ET) is the mainstay of treatment for the whole course of disease treatment (8).